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Abstract
Background: Congenital hearing loss (CHL) is diagnosed in 1 – 2 newborns in 1000, genetic factors contribute to two
thirds of CHL cases in industrialised countries. Mutations of the GJB2 gene located in the DFNB1 locus (13q11-12) are a
major cause of CHL worldwide.
The aim of this cross-sectional study was to assess the contribution of the DFNB1 locus containing the GJB2 and GJB6
genes in the development of early onset hearing loss in the affected group of participants, to determine the
population-specific mutational profile and DFNB1-related HL burden in Lithuanian population.
Methods: Clinical data were obtained from a collection of 158 affected participants (146 unrelated probands) with early
onset non-syndromic HL. GJB2 and GJB6 gene sequencing and GJB6 gene deletion testing were performed. The data of
GJB2 and GJB6 gene sequencing in 98 participants in group of self-reported healthy Lithuanian inhabitants were analysed.
Statistic summary, homogeneity tests, and logistic regression analysis were used for the assessment of
genotype-phenotype correlation.
Results: Our findings show 57.5 % of affected participants with two pathogenic GJB2 gene mutations
identified. The most prevalent GJB2 mutations were c.35delG, p. (Gly12Valfs*2) (rs80338939) and
c.313_326del14, p. (Lys105Glyfs*5) (rs111033253) with allele frequencies 64.7 % and 28.3 % respectively. GJB6
gene mutations were not identified in the affected group of participants. The statistical analysis revealed
significant differences between GJB2(−) and GJB2(+) groups in disease severity (p = 0.001), and family history
(p = 0.01). The probability of identification of GJB2 mutations in patients with various HL characteristics was
estimated. The carrier rate of GJB2 gene mutations – 7.1 % (~1 in 14) was identified in the group of healthy
participants and a high frequency of GJB2-related hearing loss was estimated in our population.
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Discussion: The results show a very high proportion of GJB2-positive individuals in the research group
affected with sensorineural HL. The allele frequency of c.35delG mutation (64.7 %) is consistent with many
previously published studies in groups of affected individuals of Caucasian populations. The high frequency
of the c.313_326del14 (28.3 % of pathogenic alleles) mutation in affected group of participants was an
unexpected finding in our study suggesting not only a high frequency of carriers of this mutation in our
population but also its possible origin in Lithuanian ancestors. The high frequency of carriers of the
c.313_326del14 mutation in the entire Lithuanian population is supported by it being identified twice in the
ethnic Lithuanian group of healthy participants (a frequency 2.0 % of carriers in the study group).
Conclusion: Analysis of the allele frequency of GJB2 gene mutations revealed a high proportion of c. 313_326del14
(rs111033253) mutations in the GJB2-positive group suggesting its possible origin in Lithuanian forebears. The high
frequency of carriers of GJB2 gene mutations in the group of healthy participants corresponds to the substantial
frequency of GJB2-associated HL in Lithuania. The observations of the study indicate the significant contribution of
GJB2 gene mutations to the pathogenesis of the disorder in the Lithuanian population and will contribute to
introducing principles to predict the characteristics of the disease in patients.
Keywords: Non-syndromic sensorineural hearing loss, GJB2 and GJB6 genes, c.313_326del14 mutation,
p.(Lys105Glyfs*5), Frequency of carriers of GJB2 gene mutation in the Lithuanian population
Background
Congenital hearing loss (CHL) is a disease of consider-
able concern in medicine nowadays. It is one of the most
common conditions and is diagnosed in 1 – 2 of 1000
newborns [1]. The incidence rises to 3.5 of 1000 before
adolescence [2]. The disorder is highly heterogeneous;
every population has a unique HL etiologic profile
dependent on ethnic, geographic, social and medical
factors. Genetic factors contribute to up to two thirds of
CHL cases in industrialized countries [3]. Most cases,
about 70 %, have non-syndromic hearing loss and about
30 % represent syndromic deafness [4]. The remaining
one-third of cases can be ascribed to environmental and
unidentified genetic factors.
At least 400 and over 150 genetic loci are associated
with syndromic and non-syndromic hearing loss respect-
ively [5, 6]. The inheritance of the disorder may be auto-
somal dominant, autosomal recessive, X recessive and
mitochondrial.
Pathogenic mutations in the DFNB1 (Deafness) locus
(13q11-12) containing GJB2 (NM_004004.5) and GJB6
(NM_001110219.2) genes are the most common cause
of non-syndromic sensorineural hereditary hearing loss
worldwide [7]. Results of the analysis of the DFNB1
locus in patients in different populations demonstrate
the leading role of that pathogenic changes in the GJB2
and GJB6 genes, which account from 10 to 40 % of
cases, have in etiologic profile of sensorineural HL [8].
To date more than 300 pathogenic mutations of the
GJB2 gene and over 20 pathogenic mutations including
gross del(GJB6-D13S1830) and del(GJB6-D13S1854) in the
GJB6 gene have been determined leading to development
of sensorineural HL [9].
GJB2 and GJB6 genes undergo coordinated transcrip-
tion, and their major expressing organs are cochlea,
placenta, hepatocytes, skin, pancreas, kidney and intestine
(GJB2 gene), and astrocytes, cochlea (GJB6 gene) [10].
Connexin 26, a 226 amino acid protein encoded by the
GJB2 gene (OMIM* 121011) and connexin 30, 261 amino
acid protein encoded by the GJB6 gene (OMIM* 604418),
form connexons. These homo- or heteromeric structures
compose gap junctions and are essential in the transport
of K+, Ca2+ ions, IP3, and other small molecules between
many cells in an organism including the supporting cells
in the inner ear, and provide a direct pathway of commu-
nication for intercellular electrical and chemical signaling.
The altered recycling of K+ to the endolymph of the coch-
lea disturbs the repolarization of the hair cell membrane
and formation of an auditory nerve impulse [11].
The disease characteristics (severity, symmetry, age of
onset, etc.) of sensorineural HL linked with DFNB1 vary
and were shown to be dependent on the GJB2 and/or
GJB6 genotype and the nature of the pathogenic mutation
[12]. Most GJB2 and GJB6 mutations are associated with
autosomal recessive non-syndromic hearing loss, but sev-
eral dominant mutations, causing sensorineural HL or
syndromic hearing loss (KID (MIM 148210), Vohwinkel
(MIM 124500) syndromes, palmoplantar keratoderma
(MIM 148350)) have been described [13].
Analysis of the mutational spectrum in the DFNB1
locus, genotype – phenotype correlation, and analysis of
the burden of DFNB1-related hearing loss have been
performed in many countries. The aim of our cross-
sectional study was to assess the contribution of GJB2
and GJB6 gene mutations to the development of early
onset hearing loss and determine the mutational profile
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in the affected group of participants in the Lithuanian
population and to analyse the burden of GJB2 and GJB6
gene mutations in our population, adding missing puzzle
piece to the genetics of congenital hearing loss.
Methods
Study design
We performed cross-sectional study using data of the two
observational projects: DEAFGEN and LITGEN. One of
the aims of DEAFGEN is to identify pathogenic mutations
of known genes associated with hereditary hearing loss and
characterize their phenotypes. The aim of the LITGEN pro-
ject was to perform wide scale genomic studies of the popu-
lation of Lithuania and to identify genomic regions of
hypothetical Lithuanian which are significant for health.
Data and results of whole genome, whole exome and
genome-wide genotyping becomes the background for the
reference genome of the population of Lithuania and a var-
iety of studies related with monogenic and complex dis-
eases in the population of Lithuania.
We enrolled two groups of participants (DEAFGEN
group: individuals affected with early onset HL and LITGEN
group: individuals of ethnic Lithuanian population) in the
current study, and collected data and venous blood samples
for the clinical and genetic analysis. Population-specific
DFNB1 locus mutation profile was determined in both
groups of participants, genotype – phenotype correlation
analysis performed in affected group of participants (DEAF-
GEN), and burden of DFNB1-related HL in our population
assessed (LITGEN).
Recruitment of participants with non-syndromic
sensorineural HL (DEAFGEN project)
Patients affected with early onset (before 5 years of
age) non-syndromic hearing loss referred to the
Vilnius University Hospital Santariskiu Clinics Centre
for Medical Genetics and Centre of Ear, Nose and
Throat from 2010 to 2015 were enrolled in this study.
Demographic data and medical records were obtained
and physical examination and genealogy analysis were per-
formed. In the presence of several affected relatives in the
family, only one (randomly chosen) was recruited to the
study to avoid bias of analysis.
Subgroups of affected participants were formed accord-
ing to the results of the analysis of disease severity,
symmetry and three generation genealogy. The participant
was assigned to the positive genealogy subgroup if at least
one relative with early onset hearing loss was determined
in the family or negative genealogy subgroup – if the case
was apparently sporadic.
Clinical evaluation of the affected group
All participants in the study were assessed in accordance
with age-specific specialised audiological evaluations.
Pure-tone audiometry was obtained when possible, with
the use of a diagnostic audiometer in a soundproof
booth, in accordance with ISO standards. The threshold
values in decibels (dB) for 0.5, 1, 2 and 4 kHz were aver-
aged for both ears (pure-tone average PTA). In cases
without pure-tone audiometry, the threshold of the wave
V of the click-evoked auditory brainstem responses ABR
or auditory steady state response ASSR were used to
calculate the hearing level. The definition of the degree
and type of HI was based on the most recent audiogram
available. The degree of HL was classified according to
the PTA (or extrapolated auditory brainstem responses
value) as mild (21–40 dB), moderate (41–70 dB), severe
(71–90 dB), or profound (>90 dB). The severity of deaf-
ness was defined by the degree of hearing loss in the bet-
ter ear. Asymmetry was defined if the PTA between ears
revealed the difference of 15 dB or greater.
Venous blood samples and written informed consent
forms of affected participants or their parents (in the case
of minors under the age of 16 years) were collected for the
‘The genomics of congenital/hereditary hearing loss: impli-
cation in disease pathogenesis, influence to phenotypic
expression and treatment efficiency’ (acronym: DEAFGEN)
project. The approval to conduct the DEAFGEN pro-
ject was provided by the Vilnius Regional Research
Ethics Committee.
Recruitment of ethnic Lithuanian population group of
healthy individuals (LITGEN project)
The group of healthy participants consisted of 98
unrelated adult individuals. This group represents the
pure ethnic Lithuanian population due to the strict
criteria of the enrolment conferring the uniqueness of
this group: all self-reported healthy study participants
indicated at least three generations of Lithuanian ethni-
city and residency in the same ethno-linguistic region.
The data, venous blood samples and written informed
consent forms were collected from individuals (trios)
who were invited to the primary healthcare centers in
the different regions of Lithuania (West, North, South
Zemaitija and West, East, South Aukstaitija) in the
period 2011–2013 for the ‘Genetic diversity of the
population of Lithuania and changes of its genetic
structure related with evolution and common diseases’
(acronym: LITGEN) project. The approval to conduct
the LITGEN project was provided by the Vilnius
Regional Research Ethics Committee. No follow-up or
exposure was performed.
Genetic analysis in affected group of participants
Whole genomic DNA was extracted from peripheral
blood following the standard phenol-chloroform ex-
traction protocol.
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Polymerase chain reactions (PCR) of coding se-
quence and sequences flanking splicing site mutation
c. − 23 + 1G >A (rs80338940) of the GJB2 and GJB6 genes
were performed using specific primers designed with
Primer Blast (NCBI) software [14] (see Additional file 1).
Both strands of PCR products were sequenced with
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, USA). Capillary electrophoresis was carried
out with 3130xL Genetic Analyser (Applied Biosystems,
USA). Fluorescent signals were analysed with Se-
quence Analysis v5.1 software (Applied Biosystems,
USA). The sequences obtained were aligned with the
reference sequence of the GJB2 (NCBI NM_004004.5)
gene. The sequence variants were analyzed in the Human
Gene Mutation Database [15] and Connexin Deafness
Homepage [16] Segregation analysis was performed by se-
quencing the GJB2 gene to the parents of the affected
participants.
The multiplex PCR assay designed by del Castillo [17]
was used to detect the del(GJB6-D13S1830) and del(GJB6-
D13S1854) mutations in the group of affected participants
if GJB2 mutations were not identified or only one hetero-
zygous GJB2mutation was identified.
The frequencies of the DFNB1 mutations were defined
and inactivating as well as non-inactivating mutations
assessed. After the genetic testing, three major sub-
groups GJB2(+), GJB2(+/−) and GJB2(−) were formed to
perform the statistical analysis of genotype – phenotype
correlation. GJB2(+) subgroup was divided into classes
of genotypes according to possession of inactivating
(frameshift) or non-inactivating (missense) mutation to
determine their different impact on the characteristics of
the disease.
Genetic analysis in group of ethnic Lithuanian population
Genomic DNA was extracted from blood using the
phenol–chloroform extraction method or automated
nucleic acid purification using paramagnetic particles
(TECAN Freedom EVO® 200, Tecan Schweiz AG,
Switzerland). Next-generation exome sequencing after in-
solution capture enrichment (TargetSeq™, Life Technolo-
gies or SureSelect, Agilent) with an average of a 40-fold
coverage was performed at the Department of Human
and Medical Genetics, Faculty of Medicine, Vilnius
University with the use of a 5500 SOLiD™ Sequencer
according to the optimised manufacturer’s protocols.
Sequence alignment and secondary and tertiary analysis
performed using LifeScope™ Genomic Analysis Software
v2.5. The Genome Analysis Toolkit’s (GATK) Combine-
Variants tool [18, 19] was used to combine all identified
genomic variants from 98 individuals into single VCF file.
The genomic variants identified were annotated using the
Annovar v.2015mar22 [20] program. Each identified GJB2
and GJB6 gene variant was checked by analysing
individuals’ BAM files using the visualisation tool Integra-
tive Genomics Viewer (IGV) [21].
Statistical analysis
Hearing loss characteristics (severity and symmetry),
family history and allele frequencies were treated as out-
come variables in the analysis. Results of genetic testing
(GJB2 and GJB6 genotypes) were treated as predictors.
Categorical variables were expressed as absolute num-
bers and percentages. The binomial exact test was applied
to calculate a confidence interval 95 % for a proportion.
The homogeneity hypothesis between two variables
was tested using Pearson’s chi-square. Logistic regres-
sion analysis was conducted to assess the impact of
GJB2 gene mutations on HL severity and positive
family history. P-values less than 0.05 were considered
statistically significant. The statistical software package
R (version 3.2.1) was used to obtain the results.
G*Power (version 3.1) was used for post hoc power
analysis of the test employed.
Results
Affected group of participants
One hundred fifty-eight participants (146 unrelated
probands), 77 female and 81 male with non-syndromic
early onset (all children aged under five) hearing loss
were enrolled in the affected group of the research. The
anonymized data of GJB2 gene genotypes are provided
in the Dataset of the group of affected individuals (see
Additional file 2, the number given to each participant
does not enable his identification).
Results of clinical evaluation in affected group of
participants
According to clinical evaluation profound, severe, mod-
erate and mild hearing loss was identified in 85 (53.8 %),
24 (15.2 %), 37(23.4 %), and 12(7.6 %) of the affected
participants respectively.
One hundred forty (88.6 %) individuals suffered from
symmetrical hearing loss and 18 (11.4 %) had non-
symmetric HL.
Genealogy analysis revealed 61 (41.8 %) unrelated
participants with positive family history of early onset
hearing loss and 85 (58.2 %) individuals without affected
family members (Table 1).
Research group of ethnic Lithuanian population
The group of the ethnic Lithuanian population con-
sisted of 98 unrelated, self-reported healthy indi-
viduals (49 female and 49 male participants). The
anonymised data with GJB2 and GJB6 genes geno-
types are provided in the Dataset of the group of
ethnic Lithuanian population (see Additional file 3,
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the number given to each participant does not
enable his identification).
Power analysis
Affected group of participants
The post hoc power analysis was performed for all the
tests in the study. Calculated empirical effect size ranged
from medium to large. The empirical power of the tests
was above 0.8. We present values for the empirical effect
size and power in corresponding Tables.
Ethnic Lithuanian group
Assuming medium effect size for the binomial exact test
and having sample size of 98, the calculated power is
above 0.8.
GJB2 gene mutation spectrum in affected group of
participants
GJB2 gene coding sequence analysis revealed 2 patho-
genic mutations in homozygous or compound heterozy-
gous state in 84 (57.5 %) affected unrelated participants,
5 (3.4 %) individuals had 1 mutation in heterozygous
state and 57 (39.1 %) unrelated participants had no
causative GJB2 gene mutations (Fig. 1).
A total of seven different pathogenic mutations (frame-
shift and missense) were identified in the affected group of
participants (Table 2).
The most prevalent GJB2 gene mutation in our study
group was c.35delG, p.(Gly12Valfs*2) (rs80338939),
which accounts for 64.7 % of pathogenic alleles. This
change was identified in a homozygous state in 37 unre-
lated affected individuals (44.0 % of the GJB2-positive
group), also in a heterozygous state with c.313_326del14,
p.(Lys105Glyfs*5) (rs111033253) in 28 participants
(33.3 % of the GJB2-positive group) and with other
mutations in 8 participants (9.5 % in GJB2-positive
group) (Table 3).
The second most frequent mutation in the group of af-
fected participants was c.313_326del14, p.(Lys105Glyfs*5)
(rs111033253) with a frequency 28.3 % of pathogenic
alleles. Nine unrelated affected individuals (10.7 % of the
GJB2-positive group) possess the mutation in homozygous
state, 28 individuals (33.3 %) – possess it in a heterozy-
gous state with c.35delG, p.(Gly12Valfs*2) (rs80338939)
and 2 participants possess it in compound with other
mutation (2.4 %).
Other pathogenic mutations: c.269 T > C, p.(Leu90Pro)
(rs8033894), c.101 T > C, p.(Met34Thr) (rs35887622),
and c.109G > A, p.(Val37Ile) (rs72474224) were much
rarer – each accounted for only up to 2.3 % of pathogenic
alleles and were in a heterozygous state with either of the
two most frequent mutations. The variant of unknown
significance, c.379C > T, p.Arg127Cys (rs727503066), was
assigned to pathogenic mutations due to a previous publi-
cation [22] and our observations (see Discussion).
GJB2 gene mutation spectrum in ethnic Lithuanian
population group
Data of GJB2 gene coding exon sequencing of 98 unrelated
participants were analysed.
The results revealed the heterozygous state of GJB2
mutations in 7 DNA samples (7.14 %) showing that
approximately 1 in 14 individuals in the Lithuanian popu-
lation is a carrier of the GJB2 gene mutation (Table 4).
Three healthy study participants had the c.101 T > C,
p.(Met34Thr) (rs35887622) mutation (3.1 %), and the mu-
tations c.313_326del14, p.(Lys105Glyfs*5) (rs111033253)
and c.35delG, p.(Gly12Valfs*2) (rs80338939) were discov-
ered in a heterozygous state with 2.0 % and 1.0 % carrier
frequencies respectively. A novel, previously undescribed
truncating mutation c.206delT (p.Phe69Serfs*13) was
identified in one participant (genotype frequency 1.0 %).
According to the frequency of carriers of the GJB2 gene
mutation in healthy group of our study (7.1 % or ~1 in 14)
we estimated the rate of GJB2-related sensorineural HL in
Lithuanian population – at approximately 1 in 772 in case
of non-assortative marriages.
Results of testing GJB6 gene point mutations and gross
deletions
GJB6 gene point pathogenic mutations and deletions
del(GJB6-D13S1830) and del(GJB6-D13S1854) were not
identified in our affected group of participants.
The GJB6 gene mutation c.428G >A, p.(Arg143Gln)
(rs201783640) was identified in a heterozygous state in
Fig 1 Results of GJB2 gene testing
Table 1 The results of clinical evaluation
Feature Type Counts %




Symmetry Symmetric 140 88.6
Non-symmetric 18 11.4
Genealogy Positive 61 41.8
Negative 85 58.2
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one DNA sample in the study group of healthy individuals
(carrier frequency ~1.0 %). The change was evaluated
by in silico analysis: SIFT predicted that amino acid
substitution likely affects protein function with score
0.003, Polyphen2 predicted probably damaging with
score 0.998[23]; MutationTaster2 predicted the change
to be disease causing.
Genotype – phenotype correlation analysis
To analyse genotype – phenotype correlation the group of
affected participants was divided into three major sub-
groups according to the results of GJB2 gene sequencing.
The GJB2-positive subgroup consisted of individuals with
two (homozygous or compound heterozygous) mutations
identified, the GJB2(+/−) subgroup consisted of individuals
with one heterozygous GJB2 gene mutation identified, and
GJB2-negative subgroup consisted of affected participants
with no pathogenic GJB2 gene mutations identified. The
GJB2(+) and GJB2(−) subgroups were compared with each
other to determine the difference in disease severity,
symmetry, and family history.
Data of five individuals of the GJB2(+/−) subgroup
with a single autosomal recessive mutation was not
included in the genotype – phenotype correlation
analysis to avoid bias of ascertainment.
Homogeneity tests were employed to evaluate the
impact of the DFNB1 genetic locus on the hearing loss
phenotype in the affected group of participants.
Our study results indicate that the severity of hearing
loss differs statistically significantly between the GJB2(+)
and GJB2(−) subgroups, p = 0.001 (Table 5, Fig. 2). Pro-
found HL dominates in the GJB2-positive subgroup
Table 2 Allele frequencies of pathogenic GJB2 gene mutations in the affected group of unrelated participants
Pathogenic GJB2 gene mutation Count Allele frequency (%) Prediction by in silico computational analysis
c.35delG, p.(Gly12Valfs*2), rs80338939 112 64.7 MutationTaster2 Disease causing
c.313_326del14 p.(Lys105Glyfs*5), rs111033253 49 28.3 MutationTaster2 Disease causing
c.269 T > C p.(Leu90Pro), rs8033894 4 2.3 Sift Damaging (score 0.000)
Polyphen-2 Probably damaging (score 1.0)
MutationTaster2 Disease causing
c.101 T > C p.(Met34Thr), rs35887622 4 2.3 Sift Damaging (score 0.027)
Polyphen-2 Benign (score 0.083)
MutationTaster2 Disease causing
c.167delT p.(Leu56Argfs*26), rs80338942 2 1.2 MutationTaster2 Disease causing
c.109G > A p.(Val37Ile), rs72474224 1 0.6 Sift Tolerated (score 0.717)
Polyphen-2 Probably damaging (score 1.0)
MutationTaster2 Disease causing
c.379C > T p.(Arg127Cys), rs727503066 1 0.6 Sift Damaging (score 0.0)
Polyphen-2 Benign (score 0.423)
MutationTaster2 Disease causing
Total 173 100.0
Table 3 Genotype distribution of pathogenic GJB2 gene mutations in the GJB2-positive subgroup of affected participants
GJB2 genotype Profound Severe Moderate Mild Total count %
c.[35delG];[35delG] 30 5 2 - 37 44.0
c.[35delG];[313_326del14] 20 4 4 0 28 33.3
c.[313_326del14];[313_326del14] 5 1 3 0 9 10.7
c.[35delG];[269 T > C] 1 - - 2 3 3.6
c.[35delG];[101 T > C] - - - 2 2 2.4
c.[35delG];[167delT] - - 1 - 1 1.2
c.[35delG];[379C > T] 1 - - - 1 1.2
c.[35delG];[109G > A] - - 1 - 1 1.2
c.[269 T > C];[313_326del14] - - - 1 1 1.2
c.[c.101 T > C];[313_326del14] - - - 1 1 1.2
Total GJB2 (+) 57 10 11 6 84 100.0
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while moderate and mild HL is more common in the
GJB2-negative subgroup.
To compare the influence of inactivating (frameshift)
and non-inactivating (missense) GJB2 gene mutations on
the characteristics of the disease, the GJB2(+) subgroup
was divided into two classes of genotypes I/I and I/N (I/
I two inactivating (frameshift) mutations of the GJB2
gene identified; I/N inactivating and non-inactivating
(missense) mutations of the GJB2 gene in compound
heterozygosity identified).
A statistically significant difference in the distribution
of HL severity in the classes of the GJB2(+) group was
observed, p = 8.005x10−11 (Table 6, Fig. 3), with pro-
found HL prevailing in the I/I subgroup and mild HL in
the I/N subgroup.
The influence of GJB2 gene mutations on symmetry of
hearing loss was also analysed in affected group of indi-
viduals. The difference between GJB2- positive and
GJB2-negative subgroups was not statistically significant,
p = 0.099 (Table 7, Fig. 4).
The genealogies of three generation of affected group
of individuals were analyzed to assess the heredity of
hearing loss. When more than one affected individuals
with early onset hearing loss was present in the family
assignment to the positive family history was made.
The comparison of GJB2(+) and GJB2(−) subgroups
showed a statistically significant difference between the
subgroups, p = 0.012, indicating a more frequent positive
family history in the GJB2 (+) subgroup (Table 8, Fig. 5).
We applied logistic regression analysis to evaluate the
chances of identifying the two GJB2 gene mutations if
profound/severe hearing loss vs moderate/mild hearing
loss was diagnosed. OR 3.1 (95 % CI 1.5 – 6.6; p = 0.003)
was calculated in our study group of affected individuals
meaning the probability of having GJB2 mutations is
3.1 times higher in case of profound or severe HL
(Table 9).
We also estimated the probability of identifying
GJB2 gene mutations in affected individuals with a
positive family history in our population. The results
indicate that the chances are 2.5 times higher than
they are in individuals with a negative family history,
p = 0.013 (Table 9).
Discussion
Hearing loss is considered to be a very heterogeneous
disorder. Although many genes have been associated
with hearing loss, mutations in the DFNB1 locus are to
be the most frequent cause of autosomal recessive hear-
ing loss and routine sequencing of the GJB2 gene and
testing of GJB6 gene deletions are recommended in
EMQN best practice guidelines [24].
Our study aimed to analyse the impact of DFNB1
locus mutations on the development of early onset
hearing loss in an affected group of participants in the
Lithuanian population. This group consists of 146 unre-
lated individuals. Our analysis describes a substantial
part: about 0.25–0.5 per cent of deaf people in Lithuania.
The results show a very high proportion of GJB2-positive
individuals (57.5 %) in the research group affected with
sensorineural HL compared with other Caucasian popula-
tions representing an adequate selection of patients for
genetic testing by referring physicians and/or quite high
genetic homogeneity in our population. Five individuals
(GJB2 (+/−) subgroup), amounting to 3.4 % of unrelated
affected participants were found to be heterozygous
carriers of one recessive mutation. This result fits into
Table 4 Allele frequencies and carrier frequencies of the pathogenic GJB2 gene mutations in the healthy group of Lithuanian
population
Mutation Count Allele frequency, % Carrier frequency, % (95 % CI)
c.101 T > C (p.Met34Thr) rs35887622 3 1.5 3.1 (0.6−8.7)
c.313_326del14 (p.Lys105Glyfs*5) rs111033253 2 1.0 2.0 (0.3−7.2)
c.35delG (p.(Gly12Valfs*2)) rs80338939 1 0.5 1.0 (0.1−5.6)
c.206delT (p.Phe69Serfs*13) 1 0.5 1.0 (0.1−5.6)
Total 7.1(2.9−14.2)
Table 5 Distribution of HL severity of GJB2(−) and GJB2(+)
subgroups
Profound HL Severe HL Moderate HL Mild HL Total
GJB2 (−) 20 12 19 6 57
GJB2 (+) 57 10 11 6 84
Total 77 22 30 12 141
Pearson Chi-Square 15.5 p = 0.001
Empirical effect size w = 0.7 Empirical power = 1.0
Fig 2 Distribution of HL severity in GJB2(+) and GJB2(−) subgroups
of affected group of participants
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the 95 % CI of GJB2 gene mutation carrier frequency
estimated in our population and possibly represents
only carrier status.
Second goal of our study was to assess the burden of
DFNB1-related early onset hearing loss in the Lithuanian
population. Our group of participants represents the
pure ethnic population due to the strict criteria for
enrolment guaranteeing the uniqueness of this cohort:
all 98 self-reported individuals indicated at least three
generations of Lithuanian ethnicity and residency in the
same ethno-linguistic region. Although a bigger ethnic
population group would better reflect the current state of
the amount of carriers of the GJB2 gene mutation, but our
results are nevertheless statistically reliable (p ≤ 0.05). The
overall frequency of carriers of the GJB2 gene mutation in
the healthy group of our study amounted to 7.1 %
(approx. - 1 in 14) allowing us to assess the GJB2-associ-
ated HL frequency in the Lithuanian population. It was
estimated to be approximately 1 in 772 if the assortative
marriages didn’t distort this value towards the higher edge.
The results of the high frequency of carriers of the GJB2
gene mutation in the ethnic Lithuanian groups of healthy
participants demonstrate the significant GJB2-associated
HL burden in our population.
Though the role of GJB2 and GJB6 gene alterations in
the pathogenesis of sensorineural HL is undisputed, the
structure of pathogenic changes identified in different
populations is not uniform. The GJB2 gene mutation
c.35delG, p.(Gly12Valfs*2) (rs80338939) is the most
frequent in Caucasian populations [25] and accounts for
up to 70 % of mutated GJB2 gene alleles. The c.167delT,
p.(Leu56Argfs*26) (rs80338942) mutation is prevalent in
the Ashkenazi Jewish population [26], and c.235delC,
p.(Leu79Cysfs*3) (rs80338943) is the leading GJB2 gene
mutation in Eastern populations [27]. Splicing mutations
(e.g. c. − 23 + 1G > A (rs80338940)) were found in some
populations [28]. The most prevalent GJB2 gene muta-
tion in the affected group of participants of our study
was c.35delG, p.(Gly12Valfs*2) (rs80338939). Its allele
frequency (64.7 %) is consistent with many previously
published studies in groups of affected individuals of
Caucasian populations. The frequency of the c.35delG,
p.(Gly12Valfs*2) (rs80338939) mutation in the healthy
group in our study 1.0 % is less then described in other
Caucasian populations where it can reach 3.2 % [29].
The c.313_326del14, p.(Lys105Glyfs*5) mutation
(rs111033253), formerly called c.310del14, c.312del14,
and c.314del14, truncates the GJB2 gene and conse-
quently interferes with the structural and functional
integrity of connexons. To the best of our knowledge,
this mutation has been identified previously in many
European populations with a frequency of pathogenic
alleles in the affected groups of participants from
0.5 % to 7.3 % (the highest allele frequency 7.3 %
occurs in the Polish population (Fig. 6) [30–42]. The
high frequency of the c.313_326del14, p.(Lys105Glyfs*5)
(rs111033253) (28.32 % of pathogenic alleles) mutation in
affected group of participants was an unexpected finding
in our study. The c.[313_326del14];[313_326del14] geno-
type was found in 10.7 % of the GJB2-positive group of
unrelated affected participants, suggesting not only a high
frequency of carriers of this mutation in our
Table 6 Distribution of degree of HL in I/I and I/N classes of
GJB2 (+) subgroup
Mutation type Profound Severe Moderate Mild Total
HL HL HL HL
I/I 55 10 9 0 74
I/N 2 0 2 6 10
Total 57 10 11 6 84
Pearson Chi-Square 50.0 p = 8.005x10−11
Empirical effect size w = 1.6 Empirical power = 1.0
Fig 3 Distribution of degree of HL in I/I and I/N classes of GJB2
(+) subgroup
Table 7 Distribution of HL symmetry in GJB2(+) and GJB2(−)
subgroups
Non symmetric Symmetric Total
GJB2 (−) 10 47 57
GJB2 (+) 7 77 84
Total 17 124 141
Pearson Chi-Square 2.7 p = 0.099
Empirical effect size w = 0.3 Empirical power = 0.9
Fig 4 Distribution of HL symmetry in GJB2(+) and GJB2(+) subgroups
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population but also its possible origin in Lithuanian
ancestors. The high frequency of carriers of the
c.313_326del14, p.(Lys105Glyfs*5) (rs111033253) muta-
tion in the entire Lithuanian population is supported by it
being identified twice in the ethnic Lithuanian group of
healthy participants (a frequency 2.0 % of carriers in the
study group). The assumption that there is a high rate of
carriers rate of this mutation in the Lithuanian population
may also be supported by the coincidental finding of this
mutation in the patient with syndromic type of hearing
loss – Rogers syndrome [43] and in two affected partici-
pants having single GJB2 gene mutation identified and
possibly experiencing hearing loss of some other aetiology.
The frequency of carriers of this mutation, 4.9x10−4, has
been determined in the NHLBI Exome Sequencing Project
in a group of European American descent, showing the
extreme rarity of this mutation in the healthy population
[44]. The mutation in a homozygous state has been found
in 2 out of 12 GJB2-positive study participants (16.7 %) of
Tatar ethnicity in Volga-Ural region of Russia [45]. These
numbers are too low to make comprehensive conclusions,
but homozygosity itself (with the exception of consanguin-
ity) is a marker of a higher carrier rate in that particular
population. In light of the close historical relationship
between Lithuanians and Tatars during wars in 8th – 14th
century this finding may provide a substantial basis for
further analysis or multi-populational research of migra-
tion and assimilation processes in Eurasia. Recently
literature review and GJB2 mutations cluster analysis was
published where Eastern European descent of the muta-
tion was proposed [46]. Pilot genetic screening of hearing
impairment in newborns from Grodno oblast (Belarus)
revealed c.313_326del14, p.(Lys105Glyfs*5) (rs111033253)
allele frequency 7 % and Polish origin was suggested [47].
From our analysis, we presume its Lithuanian descent.
The relatively low frequency of the c.313_326del14,
p.(Lys105Glyfs*5) (rs111033253) allele in the Latvian group
of affected participants proves that the mutation emerged
after the formation of the Baltic tribes. The higher frequen-
cies of the c.313_326del14, p.(Lys105Glyfs*5) (rs111033253)
allele amongst neighbouring countries (Poland and Grodno
oblast of Belarus) may represent the spreading of the muta-
tion due to close inter-relationships throughout the history
of Lithuania.
Besides the undoubtedly disease-causing GJB2 gene mu-
tations, several changes have been disputed in scientific
literature regarding their pathogenicity. The frequency of
carriers of the c.101 T > C, p.Met34Thr (rs35887622)
mutation was determined to be up to 6.5 % in the
Caucasian population [29] and initially was reported
as a polymorphism. The in silico computational analysis
shows contradictory results (Table 2) but later publica-
tions explored this variation in functional analysis and
concluded it to be pathogenic although with reduced
penetrance [48, 49]. The results of the large UK popula-
tion study recently published reaffirmed that this variant
is associated with mild/moderate HL [50]. The GJB2
mutation c.101 T > C (p.Met34Thr) (rs35887622) was
underrepresented in the study group of affected individ-
uals (allelic frequency 2.3 %) though its carrier rate in the
healthy group of Lithuanian population is estimated
to be 3.1 %. This finding may be explained by lower
pathogenicity of the mutation leading to the later and
milder manifestation of HL.
Another controversial GJB2 gene change c.109G > A,
p.(Val37Ile) (rs72474224) has also been debated. It was
previously reported both as polymorphism and a patho-
genic mutation [51, 52]. Although bioinformatics tools
show some inconsistency in the evaluation of pathogen-
icity, this mutation is currently classified as pathogenic
and associated with a mild to moderate phenotype [53].
The prevalence of c.109G > A, p.(Val37Ile) (rs72474224)
was found to be higher in Eastern populations and this
mutation was associated with the postnatal development
Table 8 Distribution of genealogy types in GJB2(+) and GJB2(−)
subgroups







Total 60 81 141
Pearson Chi-Square 6.3 p = 0.012
Empirical effect size w= 0.5 Empirical power = 1.0
Fig 5 Distribution of genealogy types in GJB2(+) and
GJB2(−) subgroups
Table 9 Probabilities of identification of GJB2 gene mutations
to affected individual
HL characteristics OR (95 % CI) p Empirical power
Profound/severe vs
moderate/mild HL
3.1 (1.5 − 6.6) 0.003 0.9
Positive family history vs
negative family history
2.5 (1.2 − 5.1) 0.013 0.8
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of HL [54]. In the group of affected individuals we found
one nuclear family with the AR mode of sensorineural
HL inheritance possessing the aforementioned mutation
leading to moderate HL.
The GJB2 gene mutation c.379C >T, p.(Arg127Cys)
(rs727503066) is considered to be a variant of uncertain sig-
nificance in scientific literature [55] and according to in
silico analysis (Table 2) but we classified it as a pathogenic
mutation. Our decision was based on the observation that
the mutation was identified in compound heterozygosity
with c.35delG, p.(Gly12Valfs*2) (rs80338939) and with
c.101 T >C, p.(Met34Thr) (rs35887622) mutations in two
affected family members: father and daughter (the father
having genotype c.[101 T >C];[379C >T] was not enrolled
into the study because of the later onset of HL (over 5 years
of age). This mutation was also described earlier in scientific
literature: it has been identified in a compound heterozy-
gous state with the c.35delG, p.(Gly12Valfs*2) (rs80338939)
mutation in an affected individual [22].
GJB6 gene mutations less contribute to the development
of hearing loss but several mutations associated with HL
have been described in scientific literature. Gross DFNB1
locus deletions involving the GJB6 gene – del(GJB6-
D13S1830), del(GJB6-D13S1854), del(DFNB1-131 kb) and
del(DFNB1 > 920 kb) which encompass non-translated
GJB6 sequences essential for both GJB6 and GJB2 gene
transcription have also been implicated in the pathogenesis
of sensorineural HL [56]. In Lithuania we have not
encountered any affected participant having GJB6 gene
point mutations or gross deletions indicating their
rarity in our population. These results are similar to
the previously published studies in other populations
strengthening the evidence that GJB6-related non-
syndromic hearing loss is extremely rare worldwide
[57]. In the study group of healthy individuals of
Lithuanian origin one carrier of the possibly patho-
genic (evidence based on in silico prediction) GJB6
gene mutation was identified.
The results of genotype – phenotype analysis show
the significant impact of GJB2 gene mutations on the
development of early onset non-syndromic HL in af-
fected group of Lithuanian origin. Our findings indicate
that inactivating GJB2 gene mutations were associated
with a more severe phenotype than missense mutations
– a finding compatible with previous publications [12]
and the nature of the mutations. GJB2 mutations also in
general lead to more severe HL (OR 3.1, p = 0.003) with
positive family history (OR 2.5, p = 0.013), compared
with the non-GJB2 aetiology of HL in Lithuanian popu-
lation. Several studies have made comparisons of the
characteristics of HL between GJB2-related and GJB2-
negative groups of affected individuals, and statistically
significant differences were determined in genealogy but
not in disease severity or other HL characteristics [58].
These observations may be helpful in clinical settings to
prognosticate the results of genetic testing and disease
course to the patients with HL in the Lithuanian
population.
Fig 6 Allele frequencies of c.313_326del14, p.(Lys105Glyfs*5) (rs111033253) mutation in GJB2-positive groups of affected individuals in European
populations (see references in Discussion). Adapted from Europe_political_chart available under Creative Commons Attribution-Share Alike 3.0
Unported and GNU Free Documentation Licenses
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Conclusions
Analysis of the frequency of the pathogenic GJB2
gene allele in the Lithuanian population revealed a
high proportion of c. 313_326del14 mutations in the
GJB2-positive group suggesting its possible origin in
the ancestors of the Lithuanian population. The find-
ings of high frequency of carriers of the GJB2 gene
mutation in the Lithuanian group of healthy partici-
pants led to the estimation of significant (1 in 772)
GJB2-associated HL frequency in Lithuania. The find-
ings of the study quantified the impact of mutations
in the DFNB1 genetic region to the development of
HL in the Lithuanian population indicating the sig-
nificant contribution of the GJB2 gene mutations on
the pathogenesis of the disorder. The results are useful for
establishing the principles to predict the course of the
disease in the patients with early onset of hearing loss.
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